BACKGROUND: The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor (HR)-positive metastatic breast cancer. METHODS:Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1:1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter. The primary end point was progression-free survival, with overall survival designated as a prespecified secondary outcome. RESULTS: The median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2 (hazard ratio for progression or death with combination therapy, 0.80; 95% confidence interval [CI], 0.68 to 0.94; P=0.007 by the log-rank test). The combination therapy was generally more effective than anastrozole alone in all subgroups, with no significant interactions. Overall survival was also longer with combination therapy (median, 41.3 months in group 1 and 47.7 months in group 2; hazard ratio for death, 0.81; 95% CI, 0.65 to 1.00; P=0.05 by the log-rank test), despite the fact that 41% of the patients in group 1 crossed over to fulvestrant after progression. Three deaths that were possibly associated with treatment occurred in group 2. The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups. CONCLUSIONS: The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard. (Funded by the National Cancer Institute and AstraZeneca; SWOG ClinicalTrials.gov number, NCT00075764.).
RCT Entities:
BACKGROUND: The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with hormone-receptor (HR)-positive metastatic breast cancer. METHODS: Postmenopausal women with previously untreated metastatic disease were randomly assigned, in a 1:1 ratio, to receive either 1 mg of anastrozole orally every day (group 1), with crossover to fulvestrant alone strongly encouraged if the disease progressed, or anastrozole and fulvestrant in combination (group 2). Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. Fulvestrant was administered intramuscularly at a dose of 500 mg on day 1 and 250 mg on days 14 and 28 and monthly thereafter. The primary end point was progression-free survival, with overall survival designated as a prespecified secondary outcome. RESULTS: The median progression-free survival was 13.5 months in group 1 and 15.0 months in group 2 (hazard ratio for progression or death with combination therapy, 0.80; 95% confidence interval [CI], 0.68 to 0.94; P=0.007 by the log-rank test). The combination therapy was generally more effective than anastrozole alone in all subgroups, with no significant interactions. Overall survival was also longer with combination therapy (median, 41.3 months in group 1 and 47.7 months in group 2; hazard ratio for death, 0.81; 95% CI, 0.65 to 1.00; P=0.05 by the log-rank test), despite the fact that 41% of the patients in group 1 crossed over to fulvestrant after progression. Three deaths that were possibly associated with treatment occurred in group 2. The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups. CONCLUSIONS: The combination of anastrozole and fulvestrant was superior to anastrozole alone or sequential anastrozole and fulvestrant for the treatment of HR-positive metastatic breast cancer, despite the use of a dose of fulvestrant that was below the current standard. (Funded by the National Cancer Institute and AstraZeneca; SWOG ClinicalTrials.gov number, NCT00075764.).
Authors: Jonas Bergh; Per-Ebbe Jönsson; Elisabet Kerstin Lidbrink; Maureen Trudeau; Wolfgang Eiermann; Daniel Brattström; Justin P O Lindemann; Fredrik Wiklund; Roger Henriksson Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544
Authors: J F Robertson; R I Nicholson; N J Bundred; E Anderson; Z Rayter; M Dowsett; J N Fox; J M Gee; A Webster; A E Wakeling; C Morris; M Dixon Journal: Cancer Res Date: 2001-09-15 Impact factor: 12.701
Authors: J Bonneterre; A Buzdar; J M Nabholtz; J F Robertson; B Thürlimann; M von Euler; T Sahmoud; A Webster; M Steinberg Journal: Cancer Date: 2001-11-01 Impact factor: 6.860
Authors: J M Nabholtz; A Buzdar; M Pollak; W Harwin; G Burton; A Mangalik; M Steinberg; A Webster; M von Euler Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: A Howell; J F R Robertson; J Quaresma Albano; A Aschermannova; L Mauriac; U R Kleeberg; I Vergote; B Erikstein; A Webster; C Morris Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: C K Osborne; J Pippen; S E Jones; L M Parker; M Ellis; S Come; S Z Gertler; J T May; G Burton; I Dimery; A Webster; C Morris; R Elledge; A Buzdar Journal: J Clin Oncol Date: 2002-08-15 Impact factor: 44.544
Authors: Anthony Howell; John F R Robertson; Paul Abram; Mikhail R Lichinitser; Richard Elledge; Emilio Bajetta; Toru Watanabe; Charles Morris; Alan Webster; Isaiah Dimery; C Kent Osborne Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Christoph Thomssen; Doris Augustin; Johannes Ettl; Renate Haidinger; Hans-Joachim Lück; Diana Lüftner; Frederik Marmé; Norbert Marschner; Lothar Müller; Friedrich Overkamp; Eugen Ruckhäberle; Marc Thill; Michael Untch; Rachel Wuerstlein; Nadia Harbeck Journal: Breast Care (Basel) Date: 2016-01-29 Impact factor: 2.860
Authors: Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown Journal: Proc Natl Acad Sci U S A Date: 2017-05-15 Impact factor: 11.205
Authors: Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872